Colorectal Cancer
Select Clinical Trial
Colorectal Cancer
Protocol Number: NRG GI004
Protocol Title: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
Eligibility: Men or women, ages 18 and older, diagnosed with Deficient DNA Mismatch repair metastatic colorectal cancer
Contact Information: (910) 715-2200
__________________________________________________________________________________________
Protocol Number: Alliance A021703
Protocol Title: Randomized double-blinded phase III trial of high-dose vs. standard dose of vitamin D3 in patients with previously untreated metastatic colorectal cancer.
Eligibility: Men and women, ages 18 and older with locally advanced/metastatic colorectal adenocarcinomas that have had no prior treatment for metastatic disease.
Contact Information: (910) 715-2200
_______________________________________________________________________________________
Protocol Number: 16-002 / NSABP C-14
Protocol Title: CORRECT-MRD II: Second colorectal cancer clinical validation study to predict recurrence using a circulating tumor DNA assay to detect minimal residual disease
Eligibility: Men and women age 18 and older, with stage II or III colorectal cancer, within 3 months of complete surgical resection of primary tumor.
Contact Information: (910) 715-2200
_______________________________________________________________________________________
Protocol Number: Gritstone GO-010
Protocol Title: A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination with Immune Checkpoint Blockade for Patients with Metastatic Colorectal Cancer
Eligibility: Men and women age 18 and older with unresectable, metastatic histologically documented colorectal cancer.
Contact Information: (910) 715-2200